好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2010 Annual Meeting | Criteria for Stopping and Starting Multiple Sclerosis Therapy

Thursday 04/15/10
06:45 AM - 08:30 AM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Breakfast Seminar
Gary Birnbaum, MD, FAAN
Participants should be familiar with some of the variables and difficulties involved in deciding when to start treatment with disease-modifying therapies in RRMS and when to stop such treatments in persons possibly no longer benefiting from them.
No CME available
Patient Care & Procedural Skills, Interpersonal and Communication Skills, Medical Knowledge
Trainee, General Neurologist, Specialist Neurologist
Case-based, Didactic, Interactive, Audience Participation
Event Timeline
06:30 AM - 08:30 AM Breakfast
06:45 AM - 07:15 AM When to Start Disease-modifying Therapy in MS
Brian G. Weinshenker, MD, FAAN
07:15 AM - 07:45 AM When to Stop Disease-modifying Therapy in MS
Gary Birnbaum, MD, FAAN
07:45 AM - 08:00 AM Break
08:00 AM - 08:30 AM Questions and Answers
Faculty Disclosures
Gary Birnbaum, MD, FAAN No disclosure on file
Brian G. Weinshenker, MD, FAAN Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CANbridge Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $0-$499 for serving as a Consultant for CALIBR. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.